BIOCORP
19.9.2022 07:31:35 CEST | Business Wire | Press release
Regulatory News:
BIOCORP (FR0012788065 – ALCOR / Eligible PEA‐PME), a French company specialized in the design, development, and manufacturing of innovative medical devices, and SANOFI announced the completion of the development of SoloSmart® today, on the opening of the EASD (European Association for the Study of Diabetes) annual meeting in Stockholm, Sweden. SoloSmart® is fully compatible with the pharmaceutical group's SoloStar® injection pens.
The result of the collaboration initiated in 2019 between the two companies is presented as an accessory to the Sanofi SoloStar®/ DoubleStar® insulin pens, which records information about the insulin dose, time and date of each injection and transmits it via Bluetooth to a compatible mobile application. The SoloSmart® device automatically and accurately records injected doses, eliminating the need for manual logbooks and possibly allows for adapting to new patient uses of continuous glucose monitoring systems or connected BGM.
Developed by BIOCORP's R&D department, SoloSmart® meets the latest requirements of the new European medical device regulation. Its commercial launch will begin early 2023 in the distribution networks approved by SANOFI and its partners. This partnership strategic step validates a substantial milestone - more details will be given on September 29th (half year results).
Eric Dessertenne, CEO of BIOCORP, said: "The expertise we have developed with Mallya leads us to improve and develop a new device by miniaturizing it, keeping data reliability. We are today very proud of developments achieved by our respective R&D and to present them today at the EASD, which brings together an international diabetes community. The strength of this industrial and commercial partnership has resulted in a technological achievement which will allow people living with diabetes, users of SoloStar® pens, to benefit from a solution that improves their daily life thanks to a presentation that is very compact but still secure and accurate.”
ABOUT BIOCORP
Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This smart sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of patients with diabetes. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions. The company has 70 employees. BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR).
For more information, please visit www.biocorpsys.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220918005029/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Three Weeks into France E-Invoicing Mandate: Sovos Hits Unparalleled Production Scale23.9.2026 10:00:00 CEST | Press release
With 170,000 registrants - 78x the registered network reach of the nearest tax compliance competitor - Sovos demonstrates unmatched production scale across direct clients and every software platform embedding its Compliance Network Sovos, the agentic tax compliance company, today announced that it has surpassed 170,000 organizations registrants across the Sovos-powered network – including both Sovos-branded and partner-branded approved service providers - using Sovos technology in France. By comparison, the nearest competitors registered fewer than 2,200 organizations each. The milestone represents a significant lead in production-grade e-invoicing, with Sovos handling transaction volumes that are many multiples higher than any other tax compliance vendor operating in France. "France represents the most complex continuous transaction controls mandate the world has seen, and we entered production on day one with our Global 2000 clients fully live," said Kevin Akeroyd, CEO, Sovos. "We ac
Thredd Partners with Velocity to Expand Global Payments Platform, Offer Stablecoin-Powered Money Movement23.9.2026 09:00:00 CEST | Press release
New capabilities will connect cards, fiat payment rails, and stablecoins through one integrated platform experience Thredd, the AI-first issuer processing platform, today announced the expansion of its payments platform to include stablecoin-powered money movement capabilities, through a partnership with Velocity, the stablecoin treasury and settlement platform bringing enterprises onchain. The initial rollout of these capabilities will focus on supporting B2B and B2B2B applications, including stablecoin-backed card programmes, cross-border payouts, global treasury flows and on-chain settlement. Thredd clients will now be able to convert between fiat currencies and supported stablecoins, send funds on-chain or through connected fiat rails, and use stablecoins for funding, payouts and settlement. “Stablecoins are rapidly becoming an important part of global payments infrastructure, but clients should not have to rebuild their payments stack to take advantage of them,” said Jim McCarthy,
Mentimeter Launches Three New Tools for Better Leadership23.9.2026 09:00:00 CEST | Press release
Mentimeter is launching an engagement suite with three new tools: Menti Live, Menti Form and Menti Pulse. Through interaction, insights and recommendations, the new suite enables organizations to engage people live, collect input asynchronously and track important signals over time. Today’s launch expands Mentimeter’s platform beyond live presentations, helping turn participation into new ways of understanding what people think, know and need. “Most organizations have plenty of data, but surprisingly little understanding of what their people actually think. These new tools give leaders a way to turn participation into company-wide performance – in the room, afterward and over time. That creates better input for action and, ultimately, better leadership,” says Johnny Warström, CEO and founder of Mentimeter. Three tools for different moments of engagement Menti Form collects input asynchronously. It allows for shared reflection and gives people the opportunity to contribute regardless of
EADV 2026: Galderma to Unveil New Data Advancing Understanding of Skin Diseases, Skin Longevity, and Real-world Patient Experiences23.9.2026 07:00:00 CEST | Press release
Galderma will present 19 abstracts, including two oral presentations, at the 2026 EADV Congress, with new data on skin diseases, skin longevity and real-world patient experiences New analyses from the Nemluvio® (nemolizumab) clinical development program will explore long-term data, in line with Galderma’s commitment to improving the outcomes that matter most to patients1-7 Galderma will also present new research on sensitive skin, dermatoporosis, and acne, evaluating more personalized management approaches and the role of skincare in maintaining barrier function, skin resilience, and longevity8-19 The company will also host educational activities, including a symposium on atopic dermatitis and prurigo nodularis, an Industry Expert Hub session on targeting cellular senescence for skin longevity, a Cetaphil® Innovation Forum and Meet-the-Expert sessions and masterclasses Together, these presentations reflect Galderma's commitment to advancing scientific understanding, helping to shape th
Oticon Medical Launches SmartCharger for the Ponto 5 Family23.9.2026 07:00:00 CEST | Press release
Oticon Medical’s first rechargeable solution for Ponto sound processors Oticon Medical today announces the launch of SmartCharger for the Ponto 5 family, introducing its first rechargeable solution for percutaneous sound processors and marking a new step in convenience and portability for bone anchored hearing system users. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922863462/en/ Oticon Medical today announces the launch of SmartCharger for the Ponto 5 family, introducing its first rechargeable solution for percutaneous sound processors and marking a new step in convenience and portability for bone anchored hearing system users. Powering the Ponto 5 family The launch of SmartCharger underlines Oticon Medical’s continued commitment to the Ponto family, which includes Ponto 5 SuperPower, the world’s most powerful abutment-level sound processor,1 and Ponto 5 Mini, the world’s smallest percutaneous sound processor.1 By br
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom